News

Two Accepted Abstracts at AACR 2024 Explore Clinical Applications of TK1 Biomarker

Mar 11, 2024

We are happy to announce that two abstracts on clinical applications of AroCell TK 210 ELISA have been accepted for poster presentations at the American Association of Cancer Research 2024 (AACR 2024) held from April 5 to 10 in San Diego, USA.

One of the abstracts is on the prognostic value of serum TK1 protein levels in Diffuse large B cell lymphoma (DLBCL) patients treated with a combination therapy called R-CHOP.
Below is the link for the full abstract:
https://www.abstractsonline.com/pp8/#!/20272/presentation/1871
 
The other abstract is on serum TK1 protein concentrations as a predictive marker for castration resistance in metastatic prostate cancer.
Below is the link for the abstract:
https://www.abstractsonline.com/pp8/#!/20272/presentation/11593

Healthcare day 2026

Apr 16, 2026 | ,

On April 14, IDL participated at Redeye Healthcare Day. CEO Anders Hultman presented the company and shared more about its strategy, current and future markets, and our joint venture with concile. Watch the presentation here

read more

CACLP and meeting with new distributor

Mar 27, 2026 | ,

During CACLP in Xiamen, China’s largest IVD exhibition, IDL Diagnostics had the opportunity to meet a wide range of industry players, exchange valuable insights, and further explore the fast-evolving Chinese IVD market. The trip concluded in Tianjin with our first...

read more

Partnership Meetings and CLIA Focus in China

Mar 20, 2026 | ,

Anders Hultman, Gustav Sten, Xia Jiang and Marie Torstensson have been in Shanghai, China, to meet our partners within CLIA. Currently, we have one product on the market, TPS CLIA, as well as two products in development: TK1 CLIA and UBC CLIA. The purpose of the...

read more